ArticleVeterinary research2026
LY6E regulates Pseudorabies virus early infection via impairing viral internalization.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pseudorabies virus (PRV) causes Aujeszky's disease, posing an emerging threat to the livestock industry and raising concern for human health. Host cells employ a wide range of intrinsic factors to combat viral infections; however, the host factors involved in restricting PRV entry remain poorly understood. In this study, using both human and porcine cell models, we identified a potent antiviral role of LY6E (lymphocyte antigen 6, family member E) in suppressing PRV infection. Overexpression of LY6E resulted in a significant reduction in PRV infection, whereas depletion of LY6E increased infection, supporting a promising antiviral role against PRV. Structure-function analyses identified that the proper structure of LY6E is indispensable for its full antiviral activity. Transcriptomic analysis revealed that LY6E modulates specific host signaling pathways during PRV infection without triggering global transcriptional alterations. Furthermore, LY6E was found to interact with PRV envelope glycoproteins, implying its role in regulating viral entry. Subsequent investigations revealed that LY6E does not interfere with the initial attachment of PRV to host cells but specifically impairs viral internalization. Collectively, this study identifies LY6E as a previously unrecognized host restriction factor for PRV and highlights the role of surface proteins in controling viral entry. Additionally, it broadens the antiviral spectrum of LY6E to DNA viruses, beyond its previously reported host-viral interaction in RNA viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.